Evidence map›Paper›PMID 24759226›Full record

ReviewCurrent opinion in pediatrics2014

Maternal-fetal cellular trafficking: clinical implications and consequences.

Cerine Jeanty, S Christopher Derderian, Tippi C Mackenzie

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02986698 (A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Alpha Thalassemia Major), which is not on this map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
8.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02986698 phase1terminatednot on this mapstarted 2017, after this paper: background citation

A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Alpha Thalassemia Major

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2024Enrolled6ConditionsAlpha Thalassemia Major, Hemoglobinopathy, With Thalassemia, HemoglobinopathiesArmsin utero hematopoietic stem cell transplantation
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Maternal DNA Methylation During Pregnancy: a Review.Reproductive sciences (Thousand Oaks, Calif.) · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Cerine JeantyEli and Edythe Broad Center of Regeneration Medicine and the Department of Surgery, University of California San Francisco, San Francisco, California, USA.
S Christopher Derderian
Tippi C Mackenzie
University of California, San Francisco · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Maternal and fetal immune responses to in utero HSC transplantationK08AI085042 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MACKENZIE, TIPPI · 2010 to 2014
$517k
NIAID NIH HHS K08 AI085042NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

purpose of reviewMaternal-fetal cellular trafficking (MFCT) is the bidirectional passage of cells between mother and fetus during pregnancy. This results in the presence of fetal cells in the maternal circulation, known as fetal microchimerism, and maternal cells in the fetal circulation, known as maternal microchimerism. The biologic role of this transplacental cellular trafficking during pregnancy is not known, although it has been implicated in development of the fetal immune system, tolerance mechanisms during pregnancy, tissue repair in autoimmune disease and cancer, and immune surveillance. RECENT

findingsClinical utility of MFCT has been identified in prenatal testing for aneuploidies and prediction of pregnancy complications. Additionally, this transplacental passage of cells has been implicated in the delicate balance between immunologic priming and tolerance, which can influence the occurrence of autoimmune disease and transplantation outcomes. Ongoing studies are evaluating the utility of microchimerism in predicting the risk of graft rejection in transplantation. SUMMARY: In this review, we will discuss the clinical implications of MFCT in pregnancy, fetal surgery, autoimmune disease, transplantation, and cancer.

Indexed as

AdultAneuploidyAutoimmune DiseasesChimerismFemaleFetal TherapiesGraft RejectionHistocompatibility, Maternal-FetalHumansImmune ToleranceInfant, NewbornMaternal-Fetal ExchangePregnancyPregnancy ComplicationsPrenatal Diagnosis

Identifiers

PMID24759226
PMCPMC4079801
OpenAlexW2319857066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.